Tarsus Pharmaceuticals (TARS) Receivables - Net (2021 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Receivables - Net of $100.3 million for Q1 2026, up 60.74% year-over-year from $62.4 million in Q1 2025, and up 17.97% quarter-over-quarter from $85.1 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Receivables - Net (2021 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Receivables - Net history runs 6 years deep, the most recent figure standing at $100.3 million for Q1 2026.
- In Q1 2026, Receivables - Net rose 60.74% year-over-year to $100.3 million; the TTM figure through Mar 2026 stood at $100.3 million (up 60.74% YoY), while the FY2025 annual figure was $85.1 million, up 81.9% from the prior year.
- Receivables - Net for Q1 2026 stood at $100.3 million, up from $85.1 million in the prior quarter.
- The five-year high for Receivables - Net was $100.3 million in Q1 2026, with the low at $17000.0 in Q1 2022.
- The 5-year median for Receivables - Net is $29.5 million (2024), against an average of $35.9 million.
- The sharpest annual moves came in 2022 and 2023: Receivables - Net sank 99.93% in 2022, then jumped 31441.18% in 2023.
- Tarsus Pharmaceuticals' Receivables - Net stood at $17000.0 in 2022, then soared by 97670.59% to $16.6 million in 2023, then jumped by 181.33% to $46.8 million in 2024, then jumped by 81.9% to $85.1 million in 2025, then rose by 17.97% to $100.3 million in 2026.
- Business Quant data shows TARS's Receivables - Net at $100.3 million in Q1 2026, $85.1 million in Q4 2025, and $72.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.03 Mn |
| Jun 30, 2026 | 96.03 Mn |
| Mar 31, 2026 | 100.34 Mn |
| Mar 31, 2026 | 100.34 Mn |
| Dec 31, 2025 | 85.06 Mn |
| Dec 31, 2025 | 85.06 Mn |
| Sep 30, 2025 | 72.62 Mn |
| Sep 30, 2025 | 72.62 Mn |
| Jun 30, 2025 | 58.33 Mn |
| Jun 30, 2025 | 58.33 Mn |
| Mar 31, 2025 | 62.43 Mn |
| Mar 31, 2025 | 62.43 Mn |
| Dec 31, 2024 | 46.76 Mn |
| Dec 31, 2024 | 46.76 Mn |
| Sep 30, 2024 | 29.16 Mn |
| Sep 30, 2024 | 29.16 Mn |
| Jun 30, 2024 | 29.53 Mn |
| Jun 30, 2024 | 29.53 Mn |
| Mar 31, 2024 | 29.89 Mn |
| Mar 31, 2024 | 29.89 Mn |